Women’s Health Market Size, Share & Trends Analysis Report By Application (Postmenopausal Osteoporosis, Infertility, Endometriosis & Uterine Fibroids, Menopause, PCOS), By Age, By Region, And Segment Forecasts, 2024 - 2030
- Report ID: GVR-1-68038-634-9
- Number of Pages: 130
- Format: Electronic (PDF)
- Historical Range: 2018 - 2022
- Industry: Healthcare
Market Segmentation
- Women’s Health Application Outlook (Revenue, USD Million, 2018 - 2030)
- Hormonal infertility
- Contraceptives
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Polycystic ovary syndrome (PCOS)
- Drug Outlook (Revenue, USD Million, 2018 - 2030)
- ACTONEL
- YAZ, Yasmin, Yasminelle
- FORTEO
- Minastrin 24 Fe
- Mirena
- NuvaRing
- ORTHO TRI-CY LO
- Premarin
- Prolia
- Reclast/Aclasta
- XGEVA
- Zometa
- Others
- Women’s Health Age Outlook (Revenue, USD Million, 2018 - 2030)
- 50 years and above
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Others
- Others
- 50 years and above
- Women’s Health Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
- North America Application Outlook
- Hormonal infertility
- Contraceptives
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Polycystic ovary syndrome (PCOS)
- North America Age Outlook
- 50 years and above
- Postmenopausal Osteoporosis
- Endometriosis & Uterine Fibroids
- Menopause
- Others
- Others
- 50 years and above
- U.S.
- U.S. Application Outlook
- Hormonal infertility
- Contraceptives
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Polycystic ovary syndrome (PCOS)
- U.S. Age Outlook
- 50 years and above
- Postmenopausal Osteoporosis
- Endometriosis & Uterine Fibroids
- Menopause
- Others
- Others
- 50 years and above
- U.S. Application Outlook
- Canada
- Canada Application Outlook
- Hormonal infertility
- Contraceptives
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Polycystic ovary syndrome (PCOS)
- Canada Age Outlook
- 50 years and above
- Postmenopausal Osteoporosis
- Endometriosis & Uterine Fibroids
- Menopause
- Others
- Others
- 50 years and above
- Canada Application Outlook
- North America Application Outlook
- Europe
- Europe Application Outlook
- Hormonal infertility
- Contraceptives
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Polycystic ovary syndrome (PCOS)
- Europe Age Outlook
- 50 years and above
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Others
- Others
- 50 years and above
- Germany
- Germany Application Outlook
- Hormonal infertility
- Contraceptives
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Polycystic ovary syndrome (PCOS)
- Germany Age Outlook
- 50 years and above
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Others
- Others
- 50 years and above
- Germany Application Outlook
- UK
- UK Application Outlook
- Hormonal infertility
- Contraceptives
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Polycystic ovary syndrome (PCOS)
- UK Age Outlook
- 50 years and above
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Others
- Others
- 50 years and above
- UK Application Outlook
- France
- France Application Outlook
- Hormonal infertility
- Contraceptives
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Polycystic ovary syndrome (PCOS)
- France Age Outlook
- 50 years and above
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Others
- Others
- 50 years and above
- France Application Outlook
- Italy
- Italy Application Outlook
- Hormonal infertility
- Contraceptives
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Polycystic ovary syndrome (PCOS)
- Italy Age Outlook
- 50 years and above
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Others
- Others
- 50 years and above
- Italy Application Outlook
- Spain
- Spain Application Outlook
- Hormonal infertility
- Contraceptives
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Polycystic ovary syndrome (PCOS)
- Spain Age Outlook
- 50 years and above
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Others
- Others
- 50 years and above
- Spain Application Outlook
- Denmark
- Denmark Application Outlook
- Hormonal infertility
- Contraceptives
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Polycystic ovary syndrome (PCOS)
- Denmark Age Outlook
- 50 years and above
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Others
- Others
- 50 years and above
- Denmark Application Outlook
- Sweden
- Sweden Application Outlook
- Hormonal infertility
- Contraceptives
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Polycystic ovary syndrome (PCOS)
- Sweden Age Outlook
- 50 years and above
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Others
- Others
- 50 years and above
- Sweden Application Outlook
- Norway
- Norway Application Outlook
- Hormonal infertility
- Contraceptives
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Polycystic ovary syndrome (PCOS)
- Norway Age Outlook
- 50 years and above
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Others
- Others
- 50 years and above
- Norway Application Outlook
- Europe Application Outlook
- Asia Pacific
- Asia Pacific Application Outlook
- Hormonal infertility
- Contraceptives
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Polycystic ovary syndrome (PCOS)
- Asia Pacific Age Outlook
- 50 years and above
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Others
- Others
- 50 years and above
- China
- China Application Outlook
- Hormonal infertility
- Contraceptives
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Polycystic ovary syndrome (PCOS)
- China Age Outlook
- 50 years and above
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Others
- Others
- 50 years and above
- China Application Outlook
- Japan
- Japan Application Outlook
- Hormonal infertility
- Contraceptives
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Polycystic ovary syndrome (PCOS)
- Japan Age Outlook
- 50 years and above
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Others
- Others
- 50 years and above
- Japan Application Outlook
- India
- India Application Outlook
- Hormonal infertility
- Contraceptives
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Polycystic ovary syndrome (PCOS)
- India Age Outlook
- 50 years and above
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Others
- Others
- 50 years and above
- India Application Outlook
- Thailand
- Thailand Application Outlook
- Hormonal infertility
- Contraceptives
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Polycystic ovary syndrome (PCOS)
- Thailand Age Outlook
- 50 years and above
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Others
- Others
- 50 years and above
- Thailand Application Outlook
- South Korea
- South Korea Application Outlook
- Hormonal infertility
- Contraceptives
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Polycystic ovary syndrome (PCOS)
- South Korea Age Outlook
- 50 years and above
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Others
- Others
- 50 years and above
- South Korea Application Outlook
- Australia
- Australia Application Outlook
- Hormonal infertility
- Contraceptives
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Polycystic ovary syndrome (PCOS)
- Australia Age Outlook
- 50 years and above
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Others
- Others
- 50 years and above
- Australia Application Outlook
- Asia Pacific Application Outlook
- Latin America
- Latin America Application Outlook
- Hormonal infertility
- Contraceptives
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Polycystic ovary syndrome (PCOS)
- Latin America Age Outlook
- 50 years and above
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Others
- Others
- 50 years and above
- Brazil
- Brazil Application Outlook
- Hormonal infertility
- Contraceptives
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Polycystic ovary syndrome (PCOS)
- Brazil Age Outlook
- 50 years and above
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Others
- Others
- 50 years and above
- Brazil Application Outlook
- Mexico
- Mexico Application Outlook
- Hormonal infertility
- Contraceptives
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Polycystic ovary syndrome (PCOS)
- Mexico Age Outlook
- 50 years and above
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Others
- Others
- 50 years and above
- Mexico Application Outlook
- Argentina
- Argentina Application Outlook
- Hormonal infertility
- Contraceptives
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Polycystic ovary syndrome (PCOS)
- Argentina Age Outlook
- 50 years and above
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Others
- Others
- 50 years and above
- Argentina Application Outlook
- Latin America Application Outlook
- Middle East and Africa
- Middle East and Africa Application Outlook
- Hormonal infertility
- Contraceptives
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Polycystic ovary syndrome (PCOS)
- Middle East and Africa Age Outlook
- 50 years and above
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Others
- Others
- 50 years and above
- South Africa
- South Africa Application Outlook
- Hormonal infertility
- Contraceptives
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Polycystic ovary syndrome (PCOS)
- South Africa Age Outlook
- 50 years and above
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Others
- Others
- 50 years and above
- South Africa Application Outlook
- Saudi Arabia
- Saudi Arabia Application Outlook
- Hormonal infertility
- Contraceptives
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Polycystic ovary syndrome (PCOS)
- Saudi Arabia Age Outlook
- 50 years and above
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Others
- Others
- 50 years and above
- Saudi Arabia Application Outlook
- UAE
- UAE Application Outlook
- Hormonal infertility
- Contraceptives
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Polycystic ovary syndrome (PCOS)
- UAE Age Outlook
- 50 years and above
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Others
- Others
- 50 years and above
- UAE Application Outlook
- Kuwait
- Kuwait Application Outlook
- Hormonal infertility
- Contraceptives
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Polycystic ovary syndrome (PCOS)
- Kuwait Age Outlook
- 50 years and above
- Postmenopausal osteoporosis
- Endometriosis & uterine fibroids
- Menopause
- Others
- Others
- 50 years and above
- Kuwait Application Outlook
- Middle East and Africa Application Outlook
- North America
Women’s Health Market Dynamics
Driver: Initiatives by government and non-government organizations
Governments and private organizations across the globe are increasing their focus on women’s health, which is likely to drive market growth. In developed economies, coverage provided to women is one of the key factors expected to drive the market. For instance, various coverage plans in the U.S. provide preventive services for women without copayment charges, which include folic acid supplements for women trying to get pregnant, contraceptives, and screening for breast cancer, anemia, & hepatitis B. Canada has made investments to promote the health and equality of women all around the world. The government has increased its funding to USD 1.4 billion annually, to promote women’s health from 2023. The initiative includes around USD 700 million from the annual funds for Sexual and Reproductive Health and Rights (SRHR).
Various initiatives undertaken by countries in Asia Pacific, such as Japan, India, China, Singapore, and Australia, are likely to boost the market over the forecast period. For instance, in January 2023, Australia’s Ministry of Health announced funding USD 24 million for medical and health research activities focusing on women’s health to develop novel treatments & improve patient outcomes. In addition, in May 2021, the Australian government announced an investment of USD 353.9 million in activities to improve women’s health as part of its 2021-2022 budget. The government planned to allocate and disburse this amount over the next 4 years to various organizations focusing on women’s health.
Restraint: Product lawsuits and false advertising
Manufacturers and providers of OTC medicines & supplements face significant loss of revenue on claim settlement due to lawsuits on their products. Consumers, including women, have filed lawsuits against several OTC medication and supplement manufacturers & sellers, such as Rite Aid and Bayer AG, due to false advertising and misleading information regarding the ingredients used. This includes products that are marketed to have natural ingredients when they have synthetic ones. For instance, Bayer AG was accused of falsely advertising that its multivitamin natural fruit bites brand One a Day was natural. Consumers claimed that the company used synthetic ingredients while making and marketing these products. Such activities of major players can damage consumer trust in their products and are expected to negatively impact the women’s health market over the forecast period.
The U.S. FDA claims that contraceptives containing drospirenone may increase the risk of blood clot formation. Many patients proposed the recall of pills containing drospirenone and replacing them with safer & more effective alternatives. Furthermore, in October 2022, the U.S. FDA postponed the approval of Opill for a prescription-to-OTC switch, stating that the agency needed more time to gain additional information associated with the safety & efficacy of the drug. Thus, delays in approval of new products are anticipated to restrain market growth.
Opportunity: Growing emphasis on personalized medicine
With rising global awareness regarding women's health issues, there is an increasing demand for comprehensive and personalized healthcare solutions. Advancements in medical technology, such as telehealth & genetic testing, offer avenues for enhanced accessibility and tailored treatments. The expanding focus on mental health within women's healthcare further opens doors for novel interventions. In addition, rising developments by market players toward innovation and research are also projected to offer a favorable opportunity for market growth during the forecast period. For instance, in July 2022, Lisa Health and Mayo Clinic entered into a collaboration to develop a personalized app for menopause. The app would incorporate AI technology for better menopause management. In March 2023, the partnership of Blue Care Network and Blue Cross Blue Shield of Michigan announced a new health solution to guide women through healthy menopause.
What Does This Report Include?
This section will provide insights into the contents included in this women’s health market report and help gain clarity on the structure of the report to assist readers in navigating smoothly.
Women’s health market qualitative analysis
-
Industry overview
-
Industry trends
-
Market drivers and restraints
-
Market size
-
Growth prospects
-
Porter’s analysis
-
PESTEL analysis
-
Key market opportunities prioritized
-
Competitive landscape
-
Company overview
-
Financial performance
-
Product benchmarking
-
Latest strategic developments
-
Women’s health market quantitative analysis
-
Market size, estimates, and forecast from 2018 to 2030
-
Market estimates and forecast for product segments up to 2030
-
Regional market size and forecast for product segments up to 2030
-
Market estimates and forecast for application segments up to 2030
-
Regional market size and forecast for application segments up to 2030
-
Company financial performance
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
